Market Overview

Jefferies Raises Price Target On Celgene, Says It Was 'Too Pessimistic'

Jefferies Raises Price Target On Celgene, Says It Was 'Too Pessimistic'
Related CELG
11 Biotech Stocks Moving From ASH 2017
Celgene's Lymphoma Strategy Is Its Biggest Positive, Analyst Says
Biotech Analysis Central Pharma News: Bluebird Bio's Success, Spark's Hemophilia Data, Verastems Results (Seeking Alpha)

Jefferies raised its price target from $98 to $140 on Celgene Corporation (NASDAQ: CELG) Monday and maintained a Buy rating.

Analysts led by Thomas Wel offered a “redo” of their financial model after the company provided strong guidance surrounding its Otezla launch and “encouraging feedback from doctors on the potential of new triplet regimens in myeloma.”

Wel noted that the firm’s estimates do not take into account drugs coming later in the pipeline. The revisions were “driven by extended duration and increased share" based on the firm's "expectation for strong data from new triplet regimens using Revlimid and assumptions for strong sales in first-line follicular lymphoma.”

The analyst note acknowledged that the firm had been “too pessimistic on Otezla” and it raised the 2018 estimates for Otezla from $600 million to $1.7 billion and estimated sales at $2.3 billion in 2020. The firm also included GED-301 in its valuation valuation and estimated sales of $500 million in 2020.

The $140 target price was based on 18x estimated 2016 earnings.

Celgene recently traded at $117.07, down 1.75 percent.

Image credit: Ragesoss, Wikimedia

Latest Ratings for CELG

Dec 2017Atlantic EquitiesUpgradesNeutralOverweight
Nov 2017BMO CapitalMaintainsOutperform
Oct 2017OppenheimerMaintainsOutperform

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Jefferies Thomas WelAnalyst Color Long Ideas Price Target Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (CELG)

View Comments and Join the Discussion!

Partner Center